This paper develops a mathematical model of cell state transitions in B-ALL to correlate with BCR::ABL1 status, MRD, and relapse risk using flow cytometry data.

Cancer Research Communications · Nov 26, 2025Peer-reviewedCancer Biology

Peripheral blood somatic mosaicism and clonal hematopoiesis across ancestry backgrounds

Christelle Colin, Yi-Han Tang, Mingxiang Teng, Nancy Gillis

The paper catalogs somatic mosaicism and clonal hematopoiesis mutations across diverse ancestry groups, finding ancestry-specific mutation patterns and associations with tumor types and age.

medRxiv · Mar 21, 2025 · PreprintGenetic & Genomic Medicine

Clonal hematopoiesis is associated with increased toxicity in large B-cell lymphoma patients treated with chimeric antigen receptor T cell therapy

Neeraj Y. Saini, David M. Swoboda, Uri Greenbaum, Jungsheng Ma, Romil D. Patel, Kartik Devashish, Kaberi Das, Mark R. Tanner, Paolo Strati, Ranjit K. Nair, Luis Fayad, Sairah Ahmed, Hun Ju Lee, Swaminathan P. Iyer, Raphael Eric Steiner, , Koichi Takahashi

This study finds that clonal hematopoiesis mutations, particularly in DNMT3A, TET2, and ASXL1, are linked to increased toxicity in patients undergoing anti-CD19 CAR T-cell therapy for large B-cell lymphoma.

bioRxiv · Sep 28, 2021 · PreprintGenetics

Oncologic Therapy Shapes the Fitness Landscape of ClonalHematopoiesis

Kelly L. Bolton, Ryan N. Ptashkin, Teng Gao, Lior Zvi Braunstein, Sean M. Devlin, Daniel John Kelly, Minal A. Patel, Antonin Berthon, Aijazuddin Syed, Mariko Yabe, Catherine Callaghan Coombs, Nicole M. Caltabellotta, Mike Walsh, Kenneth Offit, Zsofia Kinga Stadler, , Elli Papaemmanuil

The paper shows oncologic therapy increases clonal hematopoiesis with DDR mutations, which predicts risk of therapy-related myeloid neoplasms.

bioRxiv · Nov 20, 2019 · PreprintGenetics